We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Individual Proteins and their Interactions Simultaneously Visualized

By Biotechdaily staff writers
Posted on 28 Mar 2007
Expression and interaction of fluorescently labeled proteins makes living cells glow in different colors. More...
A novel assay allows simultaneous detection of individual proteins and their interactions in living cells.

Scientists from the GSF Research Centre for Environment and Health (Neuherberg, Germany) have engineered proteins to constantly emit red or blue fluorescent signals and to produce an additional yellow fluorescent signal upon interaction. Dr. Ruth Brack-Werner, director of the GSF Institute of Molecular Virology (IMV), explained the decisive advantage of the new approach: "In previous assays, signals were generated only by interacting proteins, whereas the individual partners remained undetected. However, the absence of signals could not be used to rule out protein interactions since the absence of one or both interaction partners would have the same effect.” To overcome this problem, Dr. Brack-Werner and her team developed the so-called extended bimolecular fluorescence complementation (exBiFC), which allows simultaneous monitoring of individual proteins.

Dr. Brack-Werner and her colleagues' work focused on mechanisms that control replication of the human immunodeficiency virus (HIV), which causes AIDS. "HIV replication is based on the interaction of cellular proteins with viral proteins. Interactions involving viral regulatory factors have a direct impact on the amount of virus produced by the HIV host cell,” Dr. Brack-Werner said. "Preventing HIV proteins from interacting with their crucial partners is a promising approach to developing novel therapies.”

Therefore, the GSF-scientists developed and validated exBiFC with the HIV Rev protein, which is an accelerator of HIV production. Various assays investigating Rev interactions in artificial settings indicate that the activity of Rev depends on the interaction of Rev molecules with each other and with cellular proteins. The latter include Exportin 1, which transports proteins from the nucleus to the cytoplasm and RISP, a modulator of HIV gene expression discovered by the Brack-Werner team in previous studies.

Dr. Brack-Werner and her team demonstrated that exBIFC allows visualization of interactions of Rev with itself and with Exportin1 and rev-interacting shuttle protein (RISP) in living cells. In addition, they were able to compare the strengths of the interactions of Rev with its partners by analyzing the intensities of the signals in cell images.

ExBiFC has a wide range of potential applications and represents an important tool for the elucidation of protein interaction networks and discovery of novel antiviral factors. Thus, exBIFC has an enormous potential in the battle against leading global health problems such as infectious diseases and cancers.


Related Links:
GSF Research Centre for Environment and Health

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.